(Q39764670)

14 September 2017

title

DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene (English)

1 reference

14 September 2017

Ingrid Poláková

1

1 reference

14 September 2017

Dana Pokorná

series ordinal

2

1 reference

14 September 2017

Martina Dusková

series ordinal

3

1 reference

14 September 2017

Michal Smahel

series ordinal

4

1 reference

14 September 2017

language of work or name

English

0 references

publication date

8 December 2009

1 reference

14 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 September 2017

volume

28

1 reference

14 September 2017

issue

6

1 reference

14 September 2017

page(s)

1506-1513

1 reference

Human papillomavirus and HPV vaccines: a review

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Opportunities to improve the prevention and treatment of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Papillomaviruses and cancer: from basic studies to clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

DNA vaccines: precision tools for activating effective immunity against cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Targeting plasmid-encoded proteins to the antigen presentation pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Papillomavirus E6 and E7 proteins and their cellular targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Uniformity of the splicing pattern of the E6/E7 transcripts in human papillomavirus type 16-transformed human fibroblasts, human cervical premalignant lesions and carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Papillomavirus E6 proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

inferred from DOI database lookup

7 January 2021

based on heuristic

One Hundred and Twenty-Seven Cultured Human Tumor Cell Lines Producing Tumors in Nude Mice23

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.069

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.11.069

1 reference

14 September 2017

1 reference